This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pharma Stock Roundup: AGN, NVO Report Q1 Earnings, NVS to Buy Takeda's Eye Drug
by Kinjel Shah
Allergan (AGN) and Novo Nordisk (NVO) announce Q1 results. Novartis buys rights to Takeda's dry eye disease drug, Xiidra.
Radius (RDUS) Posts Narrower Q1 Loss, Misses on Revenues
by Zacks Equity Research
Radius Health (RDUS) posts narrower-than-expected Q1 loss but Tymlos sales disappoint.
Mallinckrodt (MNK) Beats on Q1 Earnings & Sales, Raises View
by Zacks Equity Research
Mallinckrodt (MNK) earnings and sales surpass estimates in the first quarter, which led to an increase in annual guidance.
Infinity (INFI) Earnings and Sales Miss Estimates in Q1
by Zacks Equity Research
Infinity (INFI) posts wider-than-expected loss in the first quarter of 2019. Sales miss estimates in the quarter.
Prothena's (PRTA) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Prothena's (PRTA) Q1 loss was narrower than expected, while revenues missed expectations.
Will Higher Expenses Dent Cronos' (CRON) Earnings in Q1?
by Zacks Equity Research
Apart from the regular top and bottom-line numbers, investors will focus on Cronos' (CRON) pipeline progress, when it reports Q1 results.
Bausch's (BHC) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Bausch (BHC) Q1 earnings surpass estimates, while revenues miss the same. The increase in guidance was impressive.
ImmunoGen (IMGN) Misses on Earnings & Revenues in Q1
by Zacks Equity Research
ImmunoGen (IMGN) reports wider-than-expected loss in Q1 and misses revenue estimates.
Exelixis (EXEL) Earnings & Revenues Beat Estimates in Q1
by Zacks Equity Research
Exelixis's (EXEL) earnings and revenues beat expectations in the first quarter on strong sales of Cabometyx.
Celgene (CELG) Q1 Earnings Beat Estimates on Revlimid Sales
by Zacks Equity Research
Celgene (CELG) beats on earnings and sales in the first quarter of 2019.
AbbVie (ABBV) Beats on Q1 Earnings & Sales, Raises EPS View
by Zacks Equity Research
AbbVie (ABBV) beats first-quarter estimates for both earnings and revenues. Biosimilar competition impacts Humira sales in ex-U.S. markets. Growth in Imbruvica sales offsets Humira decline.
Biogen (BIIB) Beats on Q1 Earnings, Spinraza Drives Sales
by Zacks Equity Research
Biogen (BIIB) beats estimates for both earnings and sales in the first quarter fueled mainly by strong performance of its muscle disease drug, Spinraza in international markets.
Novartis (NVS) Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Novartis (NVS) beats on Q1 earnings, sales marginally miss estimates.
The Zacks Analyst Blog Highlights: Roche, Danaher, BlackRock, Kinder Morgan and Allstate
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Roche, Danaher, BlackRock, Kinder Morgan and Allstate
Top Research Reports for Roche, Danaher & BlackRock
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Roche (RHHBY), Danaher (DHR) and BlackRock (BLK).
Is a Beat in Store for AbbVie (ABBV) This Earnings Season?
by Zacks Equity Research
Strong growth of Imbruvica and Mavyret are expected to drive AbbVie (ABBV) first-quarter sales. Declining ex-U.S. Humira sales are likely to be an overhang on the top line.
Roche's (RHHBY) Q1 Sales Strong on Solid Demand for New Drugs
by Zacks Equity Research
Roche's (RHHBY) performance in the first quarter of 2019 is driven by solid strength of new drugs, which more than offset competition from biosimilars.
Novartis' (NVS) BLA for Ophthalmology Drug Accepted by FDA
by Zacks Equity Research
The FDA accepts Novartis' (NVS) BLA seeking approval for brolucizumab for the treatment of wet AMD.
Bristol-Myers' Shareholders Vote for Celgene Acquisition
by Zacks Equity Research
Bristol-Myers' (BMY) gets a green signal from a majority of its shareholders for the merger with Celgene Corporation.
Ophthotech Gets Rights to Gene Therapy for BEST Disease
by Zacks Equity Research
Ophthotech (OPHT) obtains development/commercialization rights to AAV gene-therapy program for BEST1-related retinal diseases from Penn and UFRF.
Biotechnology Market on a Tear: 5 ETFs in Spotlight
by Sweta Jaiswal, FRM
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.
J&J (JNJ) to Kick-start Pharma Q1 Earnings: What's in Store?
by Zacks Equity Research
J&J's (JNJ) sales growth in first-quarter 2019 is expected to be hurt by generic/biosimilar headwinds in the Pharma unit.
J&J Stock on an Uptrend This Year So Far: More Room to Run?
by Zacks Equity Research
J&J (JNJ) performs better than the industry in 2019 so far and looks well poised to sustain the momentum in the rest of the year.
Exelixis (EXEL) Rallies 22.4% YTD: What to Expect Ahead?
by Zacks Equity Research
Exelixis (EXEL) performance has been impressive so far in 2019 on the back of label expansion of Cabometyx.
Puma Biotech Adds Two Cohorts to Nerlynx Label Expansion Study
by Zacks Equity Research
Puma Biotech (PBYI) increases cohorts in the phase II SUMMIT basket study on Nerlynx for cancer patients suffering tumors with activating EGFR or HER2 mutations.